We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current INXB market cap is 38.86M. The company's latest EPS is USD -63.2506 and P/E is -0.21.
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|
| USD (US$) | USD (US$) | ||
| Total Revenue | 0 | 100k | 0 |
| Operating Income | -49.21M | -185.51M | -46.8M |
| Net Income | -49.27M | 1.83B | -43.86M |
| Year End 31 December 2023 | 2022 | 2023 |
|---|---|---|
| USD (US$) | USD (US$) | |
| Total Revenue | 1.32M | 1.63M |
| Operating Income | -115.32M | -152.75M |
| Net Income | -115.33M | -154.96M |
| Quarter End | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|
| USD (US$) | USD (US$) | ||
| Total Assets | 28.22M | 258.42M | 222.56M |
| Total Liabilities | 38.99M | 39.05M | 44.1M |
| Total Equity | -10.77M | 219.37M | 178.47M |
| Year End 31 December 2023 | 2022 | 2023 |
|---|---|---|
| USD (US$) | USD (US$) | |
| Total Assets | 16.65M | 26M |
| Total Liabilities | 23.95M | 33.97M |
| Total Equity | -7.3M | -7.97M |
| Market Cap | 38.86M |
| Price to Earnings Ratio | -0.21 |
| Price to Sales Ratio | 20.35 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | -4.17 |
| Dividend Yield | - |
| Shares Outstanding | 2.45M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.32 (2.06%) |
| Company Name | Inhibrx Biosciences Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.inhibrx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
